The short-time effects of chemotherapy with combinations of hydroxycamptothecine and oxaliplatin in treatment of advanced colorectal cancer

By Sun Yuanjue   Zhao Hui   Guo Yuewu   Lin Feng   Cai Xun   Tang Xiaochun   Yao Yang  

The Chinese-German Journal of Clinical Oncology, Vol. 6, Iss. 1, 2007-02 ,pp. : 40-43

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer

By Dupont Jeanette   Jensen Helle A.   Jensen Benny V.   Pfeiffer Per  

Acta Oncologica, Vol. 46, Iss. 3, 2007-01 ,pp. : 330-335

Informa Healthcare

Access to resources Recommend Favorite

Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study

By Santini Daniele   Vincenzi Bruno   Schiavon Gaia   Di Seri Marisa   Virzí Vladimir   Spalletta Bruno   Caricato Marco   Coppola Roberto   Tonini Giuseppe  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 613-620

Springer Publishing Company

Access to resources Recommend Favorite

Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer

By Hütter G.   Szélenyi H.   Deckert P.   Keilholz U.   Thiel E.  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 2, 2004-08 ,pp. : 178-184

Springer Publishing Company

Access to resources Recommend Favorite

Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer

By Quek Richard   Lim Wan Teck   Foo Kian Fong   Koo Wen Hsin   A-Manaf Afidah   Toh Han Chong  

Acta Oncologica, Vol. 46, Iss. 7, 2007-01 ,pp. : 1032-1034

Informa Healthcare

Access to resources Recommend Favorite